HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JAMA Study Finds E-Cigarettes, More Than NRTs, Help With Smoking Cessation During Pregnancy

Executive Summary

As authors of JAMA study say theirs and others' research might influence regulatory policy on e-cigarettes’ use in smoking cessation, FDA publishes latest batch of warnings to businesses selling the products without pre-market approval required from the agency.

You may also be interested in...

US Smoking Cessation Options Could Expand Behind Achieve Life’s Cytisinicline Studies

Achieved Life would seek approval as Rx smoking cessation drug, but ingredient has history of safety and efficacy available OTC in other countries, says lead researcher in study published in Journal of the American Medical Association.

US Has Pieces For Solving Policy Puzzle To Spur Spread Of Smoking Cessation Products, Programs

Former FDA tobacco programs chief Mitch Zeller says needed is commitment from White House to require reduction in nicotine levels in tobacco products and movement by FDA on finalizing rules prohibiting use of menthol and other flavors in cigarettes and some cigars.

US Smoking Cessation Clinical Trials Guidance 'Does Not Envision' Flexibility On Indications

FDA final guidance maintains limit on secondary endpoints allowed for trials, which could dissuade some investment in research for NDAs for smoking cessation products. NRT developers could find more room for novel product proposals from changes to some phrasing.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts